Comac Medical
Comac Medical is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
A Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe ulcerative colitis
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
Phase 3, double-blind, placebo-controlled, multicentre study on the efficacy and safety of human plasma derived antithrombin (Atenativ) in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass
Sponsor Octapharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2, randomized, double-blind, placebo-controlled, parallel group, 3-arm, multinational, multicenter, proof-of-concept study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in adult participants with severe alopecia areata
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who completed a previous lunsekimig CRSwNP clinical study
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
Randomized, placebo-controlled, double blind, multi-centre Phase IIb stuDy to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) – DHELIVER
Sponsor Cellaïon SA
- Start (EU)
- Latest update
- Estimated end
A randomized Phase 2, double-blind, placebo-controlled, parallel-group, 2-arm study to assess the efficacy, safety, and tolerability of subcutaneous lunsekimig in adult participants with chronic rhinosinusitis with nasal polyps (CRSwNP)
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) therapy with factor Xa inhibitor.
Sponsor Octapharma AG
- Start (EU)
- Latest update
- Estimated end
A single-centre, single-dose, open label, non-randomized, parallel group, clinical pharmacology study of CHF 6001 in asthmatic adolescent patients and in asthmatic adult patients as control group
Sponsor Chiesi Farmaceutici S.p.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
An Open-label, Randomized, Three-period, Crossover Study to compare the Pharmacokinetics of GB1211 upon dosing a capsule under fasting condition and a tablet under fasting and fed conditions in healthy volunteers.
Sponsor Galecto Biotech AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
Evaluation of the effects of oral nicotine substitutes (1.5mg lozenge) on the craving in moderate smokers placed in non-smoking situations. A randomized, double-blind, placebo-controlled parallel groups trial.
Sponsor Pierre Fabre Medicament
- Start (EU)
- Latest update
- Estimated end
- Not reported
HepaStem Long-Term Safety Registry – Registry for Patients who have been administered HepaStem
Sponsor Cellaïon SA
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Comac Medical?
The 2026-10-09 snapshot links Comac Medical to 11 distinct CTIS trials. Recorded services include Regulatory services, Project management, Clinical monitoring, Safety reporting & pharmacovigilance, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Comac Medical?
The most frequently recorded therapeutic areas are Gastroenterology, Immunology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Comac Medical conducted?
The linked trials record locations in 20 countries, including Bulgaria, Poland, Belgium, Spain, France. These are trial locations, not confirmed office locations or countries where Comac Medical delivered services.
What can this page tell me about Comac Medical's trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Comac Medical. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Comac Medical Ltd.